Editorial: early PSA-testing after radical prostatectomy-the truth behind the scenes

Affiliations

Editorial

Julian Hanske et al. Transl Androl Urol. 2019 Jul.

. 2019 Jul;8(Suppl 3):S307-S309.

doi: 10.21037/tau.2019.06.08.

¹ Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
Preisser F, Chun FKH, Pompe RS, Heinze A, Salomon G, Graefen M, Huland H, Tilki D. Preisser F, et al. Eur Urol. 2019 Jul;76(1):106-114. doi: 10.1016/j.eururo.2019.01.048. Epub 2019 Feb 14. Eur Urol. 2019. PMID: 30772034

1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. 2019. Available online: https://seer.cancer.gov/statfacts/html/prost.html.
1. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-37. 10.1016/j.eururo.2013.09.046 - DOI - PubMed
1. Martini-Klinik 2019. Available online: https://www.martini-klinik.de/die-martini-klinik/eine-einmalige-klinik/
1. van den Bergh R, Gandaglia G, Tilki D, et al. Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. Eur Urol Focus 2019;5:171-8. 10.1016/j.euf.2017.07.003 - DOI - PubMed
1. Ward JF, Moul JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2005;2:174-82. 10.1038/ncpuro0145 - DOI - PubMed